Conditions: Acute Myeloid Leukemia
Keywords: Acute Myeloid Leukaemia, AML
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 74
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.

Detailed description:

Arms:
arm 1: AZD1152 1200 mg, iv, 7 day infusion monotherapy arm 2: LDAC 20 mg, sc, bd, 10 days (400mg per cycle)

Interventions: intervention 1: AZD1152 intervention 2: LDAC
Intervention descriptions: intervention 1: 1200 mg, iv, 7 day infusion intervention 2: 20 mg, sc, bd, 10 days

Protocol document: